Answers are grounded in this paper and cite their sources.
Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug approved for the treatment of paediatric attention-deficit/hyperactivity disorder (ADHD) in Japan. This multicentre, prospective, post-marketing surveillance study evaluated real-world safety and effectiveness of LDX in children and adolescents with ADHD in Japan. Patients aged 6 to < 18 years initiating LDX between April 2021 and September 2023 were enrolled across 24 medical institutions in Japan. Safety was assessed over 24 weeks by monitoring adverse drug reactions (ADRs), including dependence/abuse events. Effectiveness was evaluated by physicians and school teachers at baseline, and weeks 12 and 24 using the Japanese ADHD rating scale IV (ADHD-RS-IV) questionnaire. Of the 88 enrolled patients, 73 were included in the safety analysis and 57 in the effectiveness analysis. The mean (standard deviation [SD]) age was 10.4 (2.6) years; 79.5% were male and 20.5% were female. Most patients (90.4%) had received prior ADHD treatment. LDX was initiated at a mean (SD) dose of 26.8 (4.7) mg, with 72.6% continuing treatment at week 24. ADRs occurred in 30.14% of patients; the most common (in ≥ 2 patients) were decreased appetite (17.81%), weight decrease (4.11%), and aggression, insomnia, irritability, middle insomnia, and abdominal pain (each 2.74%). One serious ADR (suicide attempt with methylphenidate overdose, also considered a dependence/abuse event) was reported; LDX was discontinued and the patient recovered the following day. No other dependence/abuse events were reported. Physician- and teacher-rated ADHD-RS-IV total scores improved significantly from baseline: mean (SD) changes were − 10.1 (8.0; p < 0.0001) at week 12 and − 9.7 (8.5; p < 0.0001) at week 24 for physician-rated scores, and − 4.9 (8.5; p < 0.001) at week 12 and − 5.1 (9.7; p < 0.01) at week 24 for teacher-rated scores. Findings from this post-marketing surveillance study of LDX in paediatric patients with ADHD in Japan were consistent with its established safety profile. Patients’ ADHD symptoms improved according to both physician and teacher assessments. University Hospital Medical Information Network (UMIN) Clinical Trials Registry (identifier UMIN000046038).
No takes yet. Share an insight, caveat, or question.
Okada et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: